|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prolactin receptor and oestrogen receptor are co-ordinately expressed in human breast cancer cell lines and in human breast tumour biopsies, leading to the suggestion that the expression of these receptors may be coupled.
|
1734881 |
1992 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland.
|
24249584 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolactin receptor in breast cancer: marker for metastatic risk.
|
27658959 |
2016 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgen regulation of prolactin-receptor gene expression in MCF-7 and MDA-MB-453 human breast cancer cells.
|
1544711 |
1992 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AR and PRLR were abundant in benign breast and BCa, including triple-negative tumors.
|
28364216 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer.
|
9360527 |
1997 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, receptor-selective variants of hGH that bind the hPRL receptor but not the hGH receptor were agonistic, providing additional support that specific binding to the hPRL receptor can stimulate these breast cancer cells to grow.
|
7768908 |
1995 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we employed defined three dimensional low density/compliant and high density/stiff collagen-I matrices to investigate the effects on 17β-estradiol (E2) activity and PRL/E2 interactions in two well-characterized ERα+/PRLR+ luminal breast cancer cell lines in vitro.
|
25607819 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Heterogeneous expression of prolactin receptor, at the immunoblot and immunohistochemical levels was observed in breast carcinoma specimens.
|
7534043 |
1995 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma.
|
15313907 |
2004 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In comparison with other tissues and breast cancer cells, high levels of prolactin receptor gene (PRLR) transcripts were demonstrated in parathyroid tissues.
|
22606260 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, PRLR/STAT5 signaling was recently proposed to prevent breast cancer cell dissemination and to predict favorable clinical outcomes.
|
28549597 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we compared the trafficking of HER2, which is the target of the clinically approved ADC ado-trastuzumab emtansine (T-DM1), with that of prolactin receptor (PRLR), another potential target in breast cancer.
|
28108597 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our studies have demonstrated the essential role of endogenous PRL and CDK7 in the upregulation of PRLR by E2 and provide insights for therapeutic approaches that will mitigate the transcription/expression of PRLR and its participation in breast cancer progression fueled by E2 and PRL via their cognate receptors.
|
28423697 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PIP mRNA was expressed at low levels in other human breast cancer cell lines which were prolactin receptor-positive; MCF-7 and EFM-19 lines were exceptions.
|
3667631 |
1987 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
|
28442393 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prolactin (PRL) and PRL-R over-expression are strongly implicated in breast cancer, particularly contributing to tumor growth and invasion in the more aggressive estrogen-receptor negative (ER-) disease.
|
24333596 |
2014 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Re-evaluation of the prolactin receptor expression in human breast cancer.
|
19153125 |
2009 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reverse transcription polymerase chain reaction was performed on mRNA isolated from the breast carcinoma cell line T47D, revealing two predominant receptor isoforms: the previously described long PRLr and a novel human intermediate PRLr.
|
10585417 |
1999 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since these antibodies are specifically directed against each PRLR isoform, they are valuable tools for the evaluation of breast cancer PRLR content and have potential clinical importance in treatment of this disease by providing new reagents to study the protein expression of the human PRLR.
|
21144038 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stabilization of prolactin receptor in breast cancer cells.
|
16278670 |
2006 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
|
23159947 |
2013 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The PRLR is regulated by steroid hormones; however, recent findings have suggested that PRLR may also be regulated by protein kinase C. To examine this possibility we have studied the effect of various modulators of PKC activity on PRLR binding activity and gene expression in five PRLR positive human breast cancer cell lines.
|
8320275 |
1993 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The availability of prolactin receptor-positive human breast cancer cell lines, which do (T-47D) and do not (MCF 7) express the PRA/calcyclin gene, will allow the investigation of the role, if any, of PRA in prolactin action.
|
2448309 |
1988 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present progress may have direct implications for breast cancer progression and therapy as loss of prolactin receptor-Stat5 signaling occurs frequently and BCL6 inhibitors currently being evaluated for lymphomas may have value for breast cancer.
|
23708665 |
2014 |